amlodipine/ezetimibe/rosuvastatin/telmisartan (CKD-348) / Chong Kun Dang - LARVOL DELTA

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6) (clinicaltrials.gov) - P1 | N=63 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348 (clinicaltrials.gov) - P1 | N=70 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2) (clinicaltrials.gov) - P1 | N=62 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed

Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5) (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed | N=30 ➔ 65

Enrollment change • Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6) (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3) (clinicaltrials.gov) - P1 | N=63 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348 (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed

Trial completion • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

Esperion Reports First Quarter 2023 Financial Results (GlobeNewswire) - "The Italian Medicines Agency (AIFA) approved reimbursement of bempedoic acid and the fixed-dose combination of bempedoic acid and ezetimibe for the treatment of adult patients with high blood LDL-cholesterol levels, despite taking statins or other hypolipidemic therapies. In addition, marketing approvals were obtained in Turkey for bempedoic acid and the fixed-dose combination of bempedoic acid and ezetimibe."

Reimbursement • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Heterozygous Familial Hypercholesterolemia

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5) (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Phase I Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348 (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

New P1 trial • Cardiovascular • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3) (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2) (clinicaltrials.gov) - P1; N=60; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348 (clinicaltrials.gov) - P1; N=62; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Not yet recruiting ➔ Completed

Clinical • Trial completion • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348 (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Dyslipidemia • Hypertension • Metabolic Disorders

A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348 (clinicaltrials.gov) - P1; N=60; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Dyslipidemia • Hypertension • Metabolic Disorders

Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers (clinicaltrials.gov) - P1; N=15; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Active, not recruiting ➔ Completed

Clinical • Trial completion

A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348 (clinicaltrials.gov) - P1; N=30; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Not yet recruiting ➔ Completed

Clinical • Trial completion • Dyslipidemia • Hypertension

Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet (clinicaltrials.gov) - P3; N=120; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • Combination therapy • New P3 trial • Cardiovascular • Dyslipidemia • Hypertension

Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers (clinicaltrials.gov) - P1; N=15; Active, not recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers (clinicaltrials.gov) - P1; N=15; Completed; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial

A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348 (clinicaltrials.gov) - P1; N=30; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial